Document Detail

A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis.
MedLine Citation:
PMID:  11167965     Owner:  NLM     Status:  MEDLINE    
Exorex is a new topical formulation for the treatment of psoriasis; it contains 1% coal tar and a synthetic analogue resembling components identified in banana skin (a complex of esterified essential fatty acids). To determine whether the esterified essential fatty acid complex confers any therapeutic advantage over coal tar alone, patients with chronic plaque psoriasis (n = 20) were entered into a double-blind, randomized, right/left comparison of Exorex, and Exorex without the essential fatty acid component (known hereafter as coal tar control) for 8 weeks. Target plaques were scored (0-4) for erythema, desquamation and infiltration at day 0 and at 2 week intervals throughout the study. No significant differences were detected between Exorex and coal tar control with respect to changes in the summed scores at baseline and following 8 weeks of treatment (mean difference in summed score changes from baseline between Exorex and coal tar control 0.2, 95% confidence interval - 0.44 to 0.84; P = 0.52) or in the area under the response-time curve (P = 0.16). Mean percentage improvement in summed scores of target plaques were 53.9% (SE = 4%) and 56.1% (SE = 4.9%) for Exorex and coal tar control, respectively. Results suggest that the complex of esterified essential fatty acids is not exerting any clinically important therapeutic effect in the treatment of chronic plaque psoriasis.
C H Smith; K Jackson; S Chinn; K Angus; J N Barker
Related Documents :
14609315 - Effects of amino acid deficiency on monoamines in the lateral hypothalamus (lh) in rats.
826495 - Effects of essential fatty acid deficiency and carbon tetrachloride-induced liver cirrh...
40605 - Studies on the nature of the catalytically essential ionizing group of plasmin with pk ...
12732555 - Expression of a cloned cyclopropane fatty acid synthase gene reduces solvent formation ...
8405695 - Metabolic consequences of sustained suppression of free fatty acids by acipimox in pati...
6749165 - Depletion of the reduced glutathione level in the liver and production of the mutagens ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental dermatology     Volume:  25     ISSN:  0307-6938     ISO Abbreviation:  Clin. Exp. Dermatol.     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2001-02-22     Completed Date:  2001-04-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7606847     Medline TA:  Clin Exp Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  580-3     Citation Subset:  IM    
Skin Therapy Research Unit, St John's Institute of Dermatology, St Thomas' Hospital, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Coal Tar / administration & dosage*,  adverse effects
Double-Blind Method
Drug Combinations
Fatty Acids, Essential / administration & dosage*,  adverse effects
Middle Aged
Psoriasis / drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Drug Combinations; 0/Fatty Acids, Essential; 8007-45-2/Coal Tar
Comment In:
Clin Exp Dermatol. 2001 Jul;26(5):459-60   [PMID:  11488843 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intracellular glutathione regulates tumour necrosis factor-alpha-induced p38 MAP kinase activation a...
Next Document:  Topical sucralfate in the management of peristomal skin disease: an open study.